Ground-level ozone pollution

Ground-level ozone pollution poses critical concerns for pharmaceutics, particularly in the formulation, storage, and delivery of medications. Ozone (O?) is a reactive oxidizing agent formed by sunlight-driven reactions between nitrogen oxides and volatile organic compounds. When present at ground level, it can degrade sensitive pharmaceutical ingredients, especially those prone to oxidation such as certain peptides, proteins, and unsaturated lipids. This degradation can lead to reduced potency, altered pharmacokinetics, or even the formation of harmful by-products. For inhalation therapies, which are directly exposed to ambient air during administration, ground-level ozone can interact with excipients or active ingredients, impacting the effectiveness and safety of treatment—especially for patients with pre-existing respiratory conditions.

In pharmaceutical manufacturing environments, high ozone levels can compromise cleanroom integrity and the stability of formulations, particularly in open systems or during packaging. It also imposes additional burdens on air handling and filtration systems to maintain controlled environments for production. For products stored in permeable packaging, such as certain blister packs, ozone can infiltrate and cause gradual degradation over time. This necessitates the use of ozone-resistant packaging materials and strict environmental monitoring. As pharmaceutical science advances, understanding and mitigating the effects of environmental pollutants like ground-level ozone is crucial for ensuring drug safety, efficacy, and long-term stability across various formulations.